

Dicerna Pharmaceuticals Inc  
 Form 4  
 February 04, 2014

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Halak Brian K

2. Issuer Name and Ticker or Trading Symbol  
 Dicerna Pharmaceuticals Inc  
 [DRNA]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 02/04/2014

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

PRINCETON, NJ 08542

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	02/04/2014		C	1,752,707 A <u>1</u>	1,752,707	I	By Domain Partners VIII, L.P. <sup>(2)</sup>
Common Stock	02/04/2014		C	13,004 A <u>1</u>	13,004	I	By DP VIII Associates, L.P. <sup>(2)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control**

SEC 1474 (9-02)

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying Security (Instr. 3 and 4)
					(A)	(D)	Date Exercisable	Expiration Date	
Series B Preferred Stock	(1)	02/04/2014		C		476,464	(1)	(1)	Common Stock
Series C Preferred Stock	(1)	02/04/2014		C		1,276,243	(1)	(1)	Common Stock
Warrant	\$ 7 (1)	02/04/2014		C		21,041	01/29/2014	06/26/2018	Series C Preferred Stock
Warrant	\$ 7 (1)	02/04/2014		C		21,041	01/29/2014	06/26/2018	Common Stock
Series B Preferred Stock	(1)	02/04/2014		C		3,535	(1)	(1)	Common Stock
Series C Preferred Stock	(1)	02/04/2014		C		9,469	(1)	(1)	Common Stock
Warrant	\$ 7 (1)	02/04/2014		C		156	01/29/2014	06/26/2018	Series C Preferred Stock
Warrant	\$ 7 (1)	02/04/2014		C		156	01/29/2014	06/26/2018	Common Stock

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

